- van Boxtel W, Lütje S, van Engen-van Grunsven ICH, Verhaegh GW, Schalken JA, Jonker MA, Nagarajah J, Gotthardt M, van Herpen CML. 68-Gallium-PSMA-HBED-CC PET/CT
imaging for adenoid cystic carcinoma and salivary duct carcinoma: a phase 2 imaging study. Accepted in Theranostics 09/2019. doi:10.7150/thno.38501
- Derks YHW, Löwik DWPM, Sedelaar JPM, Gotthardt M, Boerman OC, Rijpkema M, Lütje S, Heskamp S. PSMA-targeting agents for radio- and fluorescence-guided prostate
cancer surgery. Theranostics. 2019 Sep 20;9(23):6824-6839
- Bundschuh RA, Habacha B, Lütje S, Essler M. Therapy of Patients with Neuroendocrine Neoplasia-Evidence-Based Approaches and New Horizons. J Clin Med. 2019 Sep
16;8(9). pii: E1474
- Elekonawo FMK, Lütje S, Franssen GM, Bos DL, Goldenberg DM, Boerman OC, Rijpkema M. A pretargeted multimodal approach for image-guided resection in a xenograft
model of colorectal cancer. EJNMMI Res. 2019 Sep 4;9(1):86
- Lütje S, Heskamp S, Franssen GM, Frielink C, Kip A, Hekman M, Fracasso G, Colombatti M, Herrmann K, Boerman OC, Gotthardt M, Rijpkema M. Development and
characterization of a theranostic multimodal anti-PSMA targeting agent for imaging, surgical guidance, and targeted photodynamic therapy of PSMA-expressing tumors. Theranostics. 2019 May
4;9(10):2924-2938
- Lütje S, Franssen GM, Herrmann K, Boerman OC, Rijpkema M, Gotthardt M, Heskamp S. In Vitro and In Vivo Characterization of an 18F-AlF-Labeled PSMA Ligand for
Imaging of PSMA-Expressing Xenografts. J Nucl Med. 2019 Jul;60(7):1017-1022
-
Lütje S, Feldmann
G, Essler M, Brossart P, Bundschuh RA. Immune checkpoint imaging in oncology
- a game changer towards personalized immunotherapy? J Nucl
Med. 2020 Jan 10. pii: jnumed.119.237891